 Established MicroQuin and perform administrative duties associated with company filings Created business and scientific documentation for assessment by investors, collaborators, CROs and others Presented at international conferences to promote the discovery and pipeline at MicroQuin whilst striving to secure investment Established a large network of connections, both investor and non-investor related, to progress MicroQuin’s discovery through lead optimisation, pre-clinical studies and into gaining CTA approval in a 24-36 month timeframe Runner up at both European Start-up and Johnson & Johnsons Innovation competition Co-wrote patent application alongside Mewburn Ellis (patent attorney’s), familiar with IP process and the supporting information for making IP claims Performed an array of in vitro experiments to validate scientific discovery Investigated potential drug candidates through proteomic analysis and target based drug discovery techniques Compiled reports on drug candidate successes and failings offering insight on potentially new novel therapeutics Protein biochemist for the design, characterisation and production of 5 new compounds capable of being tested in in vivo models Collaborated with academics from University of Bristol and Imperial College London to perform in vivo assessment of synthetic protein based compounds to assess in vitro data in an animal model Continuing collaborations with University of Bristol and Imperial College London to progress MicroQuin research

 Interpreted regulations and chaired technical committees to debate the impact of regulations/model enhancements Validated, modified and implemented new Front Office model for Structured Issuance Notes Responding to PRA request for further information; walking the regulators through model updates; developing plans to meet regulatory demands Lead BA on establishing the required risk management practices and calculations for initial and variation margin on SFT transactions GAP analysis, business requirements gathering and documentation to define Risk model enhancements for IT Establish project governance and working groups to discuss regulatory requirements / model enhancements Provide a link between the business and IT to manage the delivery of business requirements Assess and report on Credit Risk calculations to identify exposure errors and their impact on Capital Update global margin models

 Interpreted and contextualised existing regulation to improve the Credit Risk practices of the Hedge Fund, Collateral and Liquidity Management teams Assessed Credit Risk scenario methodology to identify errors and recommend improvements Engaging senior stakeholders, globally, to gather business requirements and define a centralized, global approach to Risk management associated with Hedge Funds, Collateral and Liquidity Risk and Broker Dealers Established project governance and working groups to discuss regulatory requirements / model enhancements Developed a compliance framework for regulatory rules Defined reporting requirements across the Hedge Fund, Collateral & Liquidity Management and Financial Institutions teams

• Identifying and interpreting new regulation including ensuring alignment with the Firm’s risk management framework • Establish project governance and working groups to discuss regulatory requirements / model enhancements • Validate Credit Risk and Market Risk Models to improve risk management, meet regulatory requirements and improve risk management processes • Assess and report on Credit and Market Risk calculations to identify exposure errors and their impact on Capital • Developing a compliance framework for regulatory rules • Independent Validation – independently validating self-assessment of regulatory rules applicable to risk management and implementation of new rules • Liaising with Front Office and Risk Managers to respond to PRA requests • Advisory role across risk management and providing weekly reports to senior management of the regulatory landscape

Business Analyst - Interpreting regulatory text to define a set of requirements for BCBS239 and aligning this to the Global Data Management and MI Reporting Programme. Globally assessing alignment to new policies and standards. Project Manager - Identifying GAPs, discussing remedial activities and planning, tracking progress in alignment with the plan,engaging with stakeholders to address issues and risks weekly reporting to senior management, chairing WGs to ensure delivery

 Analyse and interpret regulatory text and model enhancements to provide interpretation and guidance to senior management Chair technical committees to debate the impact of regulations on Risk and propose an approach Manage delivery of global regulatory projects; my successes to date include delivering CRDIV Credit Risk Model enhancements and all Dodd Frank Risk requirements across 4 entities Global Risk Business Analyst ensuring BCBS239 compliance; to date this has included aligning BCBS239 Principles to the regulatory landscape, GAP analysis, defining requirements and completing the Stock taking Questionnaire for submission to the JFSA Updated Risk Policies and Procedures  GAP analysis, business requirements gathering and documentation to define Risk model enhancements for IT Establish project governance and chair working groups to discuss regulatory requirements / model enhancements Provide a link between the business and IT to manage the delivery of business requirements User Acceptance Testing (both performing and managing) Validate Credit Risk Models and processes to; improve assessment of counterparty exposure; refine downstream capital calculations; improve Model valuation add-ons and adjustments; and improve collateral management processes Assess and report on Credit Risk calculations to identify exposure errors and their impact on Capital Defining and documenting the requirements for both Credit Risk and Market Risk Intra-day Limits Monitoring processes and performing UAT to ensure Risk is being managed effectively Provide support to the CVA working group as both a Business Analyst and PMO to ensure the development and implementation of cross-asset correlation add-ons, optimization of CVA VaR to reduce CVA capital charges and enhance reporting processesI am currently covering rules pertaining to Dodd Frank, EMIR, CRD4, OTC Derivatives (Japan), MiFID 2, and MiFIR and BCBS239. BCBS246, BCBS253 and 254, Basel 3

Working across domains, with focus on finance, risk and compliance. I am involved in regulatory work regarding RRPs, FATCA, Basel 2.5/3 and ICB Reforms, and am engaged with numerous clients to implement strategic change.Additionally, I am the lead Market Risk SME and have experience in implementing / developing quantitative risk models (VaR, SVaR, GVaR, IRC, CRC), and have some experience in Credit Risk modelling (CVA). As well as implementing strategic change to ensure Market Risk best practice.

Worked within the department of gene expression and protein biochemistry designing constructs, doing expression profiles of recombinant proteins and purifying proteins for crystallization.